Intro
Ovarian cancer (OC) is considered a life-threatening disease in women with
reproductive tumours because it is the second most common cause of death in
diagnosed women worldwide.
1
Generally, the majority of cases of OC are detected when the disease has
already progressed significantly, which results in poor outcomes even if the patient
receives the correct therapies or undergoes surgery.
2
A comprehensive ultrasonographic assessment of the female reproductive organs and the
measurement of serum biomarkers such as cancer antigen (CA)-125 are the preferred
strategies to detect gynaecological cancers. 2 Novel therapeutic
modalities related to the molecular description of OC are required. However,
treatment does not reduce OC morbidity or mortality and an increased frequency of
recurrence was found even after initial treatment. 3 , 4
In the US, 21 750 OC patients and 13 940 deaths due to OC were reported in 2020,
which accounted for 1.2% of all cancer cases in that country and the 5-year survival
rate for well-treated women with OC was 48.6%.
5
A previous study in India reported that 15.7% of cases were identified at the
local stage and these cases had a 92.6% survival rate, whereas the 58% of cases that
were detected at the metastatic stage had a survival rate of 30.2%.
6
In terms of the histological classification of OC, the epithelial type is the most
common (90%), which based on their histology are either serous, mucinous,
endometrioid or clear cell tumours.
7
OC can be further classified into two subtypes known as type I and type II
carcinomas, the latter being the more fatal variant, which is thought to be caused
by continuous ovarian cycles resulting in inflammation and endometriosis.
8
Regarding parity, nulliparous women have a higher risk of OC mainly due to ongoing
regular ovulation that might increase the risk of repeated minor injury to the
superficial ovarian epithelium during the ovulation process.
9
Postmenopausal women have a high incidence rate of OC and a low survival rate.
10
This group of women have type I OC, especially those > 50 years.
8
However, premenopausal women are more likely to have hereditary OC.
8
Furthermore, a family history of having breast cancer/OC is considered the
greatest risk factor of OC; and an individual history of breast cancer similarly
increases the risk of OC.
11
Similarly, pelvic inflammatory disease (PID) is a risk factor for OC development.
12
Uterine fibroid (UF) is a benign tumour of the womb that grows mainly during
reproductive age in approximately 70% of women.
13
However, 50% of women do not show clinical signs related to UF, which might
include abdominal ache, high menstrual bleeding and anaemia.
14
The development of UF is 2–3 times more likely in obese women than in those
with average body weight.
15
Subsequently, UF might have the exactly the same pathophysiology of
reproductive organ malignancy, especially endometrial/OCs.
16
Endometriosis is a common oestrogen-related disorder found in approximately 10% of
women of reproductive age, which can be associated with pelvic pain, although
asymptomatic cases are found that sometimes result in infertility.
17
The burden of endometriosis during reproductive life changes after the
menopause, when ovarian hormones stop stimulating the lesions and the major issue is
the risk of malignant transformation.
18
Moreover, endometriosis is suggested to be associated with a significantly
increased risk of invasive OC because mutations of the AT-Rich Interaction Domain 1A
gene have been demonstrated in endometriosis, which suggests an initial stage in the
pathogenesis of endometriosis-associated ovarian cancer.
19
Prolonged inflammation is important in the formation and development of
endometriosis via the production of proinflammatory cytokines such as matrix
metalloproteinase-3, interleukin (IL)-6/IL-8, intercellular adhesion molecule-1 and
tumour necrosis factor-alpha.
20
Approximately one-third of patients with OC are asked to use contraceptive hormones
for a long time to reduce the possibility of OC recurrence.
21
In this regard, it was found that receiving contraceptive hormones
for > 15 years reduced the risk of the OC by roughly 50%.
21
This current retrospective observational study aimed to evaluate the correlation
between benign gynaecological disorders and the development of OC.
Results
This retrospective observational study enrolled 100 women with confirmed OC and other
associated gynaecological diseases. The mean ± SD age of the cohort of women with OC
was 55.0 ± 15.0 years. In terms of the age distribution, 63% (63 of 100 patients)
were aged 40–59 years, 28% (28 of 100 patients) were aged 60–79 years and 9.0% (nine
of 100 patients) were aged > 80 years ( Table 1 ). The mean ± SD BMI of the cohort
of women with OC was 28.7 kg/m 2 ; of which 80% (80 of 100 patients) were
overweight and obese. The majority of women (77%; 77 of 100 patients) were married
and illiterate (56%; 56 of 100 patients). Medical comorbidities were identified in
56 of 100 patients (56%) and were as follows: hypertension (19 of 56 patients;
33.9%); anaemia (eight of 56 patients; 14.3%); diabetes mellitus (seven of 56
patients; 12.5%); cardiac disease (six of 56 patients; 10.7%); or they had a
combination of comorbidities. A total of 37 of 100 patients (37%) had a history of a
first-degree relative with breast/OC. A total of 27 of 100 patients (27%) had a
history of current and passive smoking. Regarding parity, 20 of 100 patients (20%)
were nulliparous and 80 of 100 patients (80%) were multiparous. A total of 10 of 100
patients (10%) were infertile and had used medication for ovulation induction. Of
the 100 patients, three (3%) used oral contraceptive pills and only one (1%) had
undergone a hysterectomy.
Demographic and clinical characteristics of women ( n = 100)
with ovarian cancer (OC) that were included in a retrospective observational
study aimed to evaluate the correlation between benign gynaecological
diseases and the development of OC.
a Current and passive smoking history.
The gynaecological diseases observed in the cohort of women with OC were simple
ovarian cyst (44 of 100 patients; 44%) and benign uterine tumours (56 of 100
patients; 56%); the latter of which included UF (22 of 100 patients; 22%),
adenomyosis (15 of 100 patients; 15%), PID (13 of 100 patients; 13%) and
endometriosis (six of 100 patients; 6%) ( Table 2 ). The histological findings of the
OC tumour masses were as follows; high grade serous OC (59 of 100 patients; 59%),
mucinous OC (20 of 100 patients; 20%), low grade serous OC (nine of 100 patients;
9%), granulosa cell tumour (five of 100 patients; 5%), yolk sac tumour (four of 100
patients; 4%) and endometrioid (one of 100 patients; 1%). A total of 52 patients
(52%) had stage I/II OC and 48 patients (48%) had stage III/IV OC.
Gynaecological conditions and characteristics of ovarian cancer (OC) in women
( n = 100) included in a retrospective observational
study aimed to evaluate the correlation between benign gynaecological
diseases and the development of OC.
The identification of tumour biomarkers in the cohort of women with OC are presented
in Table 3 . Increased
levels of CA-125 (65 of 100 patients; 65%), CA19-9 (21 of 100 patients; 21%), β-hCG
(eight of 100 patients; 8%), LDH (nine of 100 patients; 9%) and CEA (two of 100
patients; 2%) were measured. Some patients had increased levels of more than one
biomarker: CA-125 + CA19-9 (nine of 100 patients; 9%), β-hCG + LDH (two of 100
patients; 2%), CA-125 + LDH (six of 100 patients; 6%) and CA-125 + β-hCG (four of
100 patients; 4%) ( Table
3 ).
Increased tumour biomarker levels of women ( n = 100) with
ovarian cancer (OC) that were included in a retrospective observational
study aimed to evaluate the correlation between benign gynaecological
diseases and the development of OC.
CA, cancer antigen; CEA, carcinoembryonic antigen; β-hCG, β human
chorionic gonadotropin; LDH, lactate dehydrogenase.
Analysis of the relationship between the origin of the benign disease and OC tumour
histology demonstrated a significant association ( P = 0.03) between
high grade serous OC histology with both benign ovarian and uterine diseases ( Table 4 ). There was a
significant association between β-hCG ( P = 0.009) and LDH
( P = 0.03) biomarkers and benign uterine tumours. There were no
other significant associations observed for the other biomarkers and benign
ovarian/uterine tumours.
Relationship between ovarian cancer (OC) histology, staging and tumour
biomarkers according to benign gynaecological disease origin in women
( n = 100) with OC that were included in a retrospective
observational study aimed to evaluate the correlation between benign
gynaecological diseases and the development of OC.
CA, cancer antigen; CEA, carcinoembryonic antigen; β-hCG, β human
chorionic gonadotropin; LDH, lactate dehydrogenase.
a χ 2 -test was used to compare categorical data and
Fisher’s exact test was used to compare categorical data when the
expected variables were < 20% of total variables; NS, no significant
association ( P ≥ 0.05).
There was a significant association ( P < 0.001) between both
adenomyosis and UF and high grade OC ( Table 5 ). A significant association
( P = 0.008) was observed between endometriosis and stages
III/IV of OC.
Relationship between ovarian cancer (OC) histology, benign gynaecological
disease origin and cancer stage in women ( n = 100) with OC
that were included in a retrospective observational study aimed to evaluate
the correlation between benign gynaecological diseases and the development
of OC.
Data presented as n of patients (%).
PID, pelvic inflammatory disease.
a χ 2 -test was used to compare categorical data and
Fisher’s exact test was used to compare categorical data when the
expected variables were < 20% of total variables; NS, no significant
association ( P ≥ 0.05).
There was a significant association ( P = 0.009) between younger age
and benign uterine diseases ( Table 6 ). There was a significant association
( P < 0.001) between no education and benign uterine diseases.
There was a significant association ( P = 0.02) between a history of
medical comorbidities and benign uterine diseases, especially hypertension
( P = 0.004). There were no significant correlations between the
menstrual status, marital status, BMI, first-degree female relative with breast/OC
and smoking status and both benign ovarian and uterine diseases. There was a
significant correlation ( P = 0.04) between the use of oral
contraceptive pills > 5 years and benign ovarian diseases. There were no
significant correlations between IUD use, parity, ovulation inducer use and
hysterectomy and both benign ovarian and uterine diseases.
Relationship between benign gynaecological disease origin and
demographic/clinical characteristics of women ( n = 100)
with OC that were included in a retrospective observational study aimed to
evaluate the correlation between benign gynaecological diseases and the
development of OC.
a χ 2 -test was used to compare categorical data and
Fisher’s exact test was used to compare categorical data when the
expected variables were < 20% of total variables; NS, no significant
association ( P ≥ 0.05).
DM, diabetes mellitus; HT, hypertension; IUD, intrauterine device.
Patients
This retrospective observational study enrolled consecutive women with confirmed
OC and other associated gynaecological diseases at Hiwa Haematology/Oncology
Hospital, Shorsh Hospital and the Maternity Teaching Hospital, Sulaimaniyah,
Republic of Iraq between 1 January 2020 and 30 June 2021. The inclusion criteria
were as follows: (i) women with confirmed primary OC based on a
histopathological evaluation of the tumour mass after surgery; (ii) women with a
history of other benign gynaecological diseases; (iii) women of any age. The
exclusion criteria were as follows: (i) women with other gynaecological
malignancies, such as endometrial cancer, cervical cancer, valvular cancer and
other secondary metastases.
Ethical approval for this study was provided by the Arab Board of Health
Specializations (no. 2/03022020-COM-UOS) following the appropriate guidelines
and regulations belonging to the declaration of Helsinki. Approval was also
provided by the Institutional Review Boards of the three hospital authorities.
Written informed consent was provided by all study participants and their data
were de-identified. The reporting of this study conforms to STROBE guidelines.
22
Data were collected using a well-designed and detailed questionnaire directly
from the patients or their relatives that included sociodemographic data such as
age, marital status, educational level, smoking status, parity; and
anthropometric data (height and weight to determine body mass index [BMI]). Data
on medical problems (such as comorbidities), a family history of OC and breast
cancer, a history of using contraceptive pills/intrauterine device (IUD), a
history of hysterectomy, as well as a history of infertility and using
medication for ovulation induction were also obtained. Information on other
gynaecological disorders was collected. The histological findings of the excised
ovarian tumour/mass and stage of OC were reported. Levels of OC biomarkers
including CA-125, cancer antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA),
β human chorionic gonadotropin (β-hCG) and lactate dehydrogenase (LDH) were
determined using enzyme-linked immunosorbent assays and the data were collected
from the patient’s records.
All statistical analyses were performed using IBM SPSS Statistics for Windows,
Version 25.0 (IBM Corp., Armonk, NY, USA). Continuous data are presented as
mean ± SD and categorical data are presented as n of patients
(%). χ 2 -test was used to compare categorical data and Fisher’s exact
test was used to compare categorical data when the expected variables
were < 20% of total variables. A P -value < 0.05 was
considered statistically significant.
Discussion
Ovarian cancer is a common gynaecological cancer worldwide, especially in older women.
23
Despite the advances in medical technology, the exact pathogenesis of OC is
not fully understood.
24
The relationship between benign gynaecological diseases and OC remains
uncertain despite ongoing research.
8
This current retrospective observational study demonstrated that 56% of the women
with OC had benign uterine diseases, most commonly UF and adenomyosis. This finding
was consistent with the results a previous large population-based case–control study
in the US that reported that multiple gynaecological diseases in women increased the
risk of OC.
25
In the current study, 22% of women with OC had UF. This finding was very
similar to the results of a population-based cohort study conducted in Denmark,
which demonstrated a strong association between benign gynaecological diseases
(especially UF) and the risk of OC.
26
An explanation of the mechanisms involved in the relationship between benign
gynaecological diseases and OC might involve hormonal changes, benign tumour risk
factors and a higher surveillance rate of women with benign conditions, which could
subsequently lead to a higher OC identification rate.
27
In the current study, 15% of women with OC also had adenomyosis, which was
similar to the findings of a previous case–control study in China that found no
significant relationship between women with UF or endometriosis and risk of OC; but
the risk of OC was high among women with adenomyosis.
28
In the current study, 13% of women with OC had PID, which was similar to the results
of a previous study conducted in Denmark, which found that women with PID had a
two-fold increased risk of subsequent OC.
29
In addition to the effect of frequent ovulation and high gonadotropin levels
on the pathogenesis of OC, inflammation plays a significant biological role in the
development of OC.
28
Moreover, PID related to genital tract infections increases the risk of OC.
30
In the current study, 6% of women with OC had endometriosis. Similarly, a previous
study undertaken in Italy reported that both endometriosis and OC had a common
pathological mechanism and shared a common preventive strategy.
31
The reason for the relationship between endometriosis and OC remains mainly
unknown, but it might be attributed to the microenvironment at the endometriosis
site. 3
1
The current study demonstrated that the most common histology was high grade serous
OC (59% of patients), which agrees with a previous retrospective study undertaken in
the Republic of Iraq that found that high grade serous OC was common (57%).
32
In the current study, 52% of women had stage I/II OC and 48% had stage III/IV
OC, which was inconsistent with the findings of a study undertaken in Maysan,
Republic of Iraq that reported that 76% of patients had stage III/IV OC.
33
This inconsistency might be attributed to better OC diagnosis and treatment
facilities in the Kurdistan Region than other areas of the Republic of Iraq.
With regard to tumour biomarkers, this current study showed that the CA-125 level was
increased in 65% of women with OC, which was similar to the results of Canadian
study that reported that CA-125 is an accurate biomarker of OC with moderate
sensitivity and high specificity.
34
The current study demonstrated a significant association ( P = 0.009)
between younger age and benign uterine diseases, which agreed with the findings of
an Italian study.
35
The current study also showed a significant association
( P < 0.001) between no education and benign uterine diseases.
This current finding was consistent with a US study that demonstrated that the risk
of OC was increased in women with low educational and socioeconomic levels, which is
possibly due to illiteracy resulting in low levels of awareness of the risk factors
preceding OC such as benign gynaecological diseases.
36
In the present study, there was a significant association ( P = 0.02)
between a history of medical comorbidities and benign uterine diseases, which was
similar to the results of a study conducted in Mexico.
37
The current study also found a significant association
( P = 0.004) between hypertension and benign uterine diseases,
consistent with the results a previous Danish study, which found that women with
hypertension had a higher risk of OC and uterine tumours.
26
The current study demonstrated a significant association ( P = 0.03)
between high grade serous OC histology with both benign ovarian and uterine
diseases. This finding was similar to the results of a US study that reported that
women with OC accompanied with a benign ovarian mass had a higher grade of cancer.
38
In the present study, there was a significant association
( P = 0.009) between β-hCG and benign uterine tumours. This current
finding parallels the results of other studies that reported the role of a β-hCG in
both OC and benign uterine tumours. 39 , 40 This current study also
demonstrated a significant association ( P = 0.03) between LDH and
benign uterine tumours, which was consistent with the results of a Japanese study
that reported that LDH levels were useful in distinguishing endometriosis-related OC
and ovarian endometrioma.
41
The current study demonstrated was a significant association
( P < 0.001) between both adenomyosis and UF and high grade OC,
findings that agreed with the results of a large population-based case–control study
in the US, which demonstrated that the risk of high grade serous OC increased with
the risk of accompanying benign gynaecological disorders.
25
The current study also found a significant association
( P = 0.008) between endometriosis and stages III/IV of OC, which
was similar to the results of a previous Italian study.
31
The current study had several limitations. First, it was undertaken during the
coronavirus COVID-19 lockdown. Secondly, the sample size was small. Thirdly, there
was a time limitation due to the fact that a postgraduate student (Soz Mustafa Hagi
Karim) was collecting the data.
In conclusion, benign gynaecological diseases are accompanied by the high risk of the
development of OC. Common benign gynaecological diseases associated with OC were
uterine fibroids and adenomyosis. The risk of OC might be further increased by a low
educational level and the presence of other comorbidities, especially hypertension.
The presence of benign gynaecological disease is a risk for high grade OC histology
and advanced stages of OC. These findings suggest that there should be mandatory
health education about OC provided to women with benign gynaecological
conditions.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.